I’m Dr. Steven Rosen, and I am pleased to introduce the first episode of The Oncology Insights Podcast. This podcast is created for professionals dedicated to advancing cancer care. In the episodes ahead, I’ll be joined by Dr. Abbie Begnaud, Associate Professor of Pulmonary and Critical Care at the University of Minnesota, and Dr. William Oh, Director of Precision Medicine at Yale Cancer Center and Smilow. Together, we will examine the latest research and essential topics that are shaping the future of oncology. In this episode of The Oncology Insights Podcast, Dr. Joseph Mikhael, Professor at TGen and Chief Medical Officer of the International Myeloma Foundation, explores the evolving landscape of multiple myeloma care. He discusses optimal drug regimens, immunotherapies, health disparities, and the promise of MRD testing and early intervention. Understand how cutting-edge strategies are extending and improving patient lives. Listen now on all major platforms! “The vast majority of patients treated with multiple myeloma today as their initial therapy should receive a quadruple.” Meet the guest: Dr. Joseph Mikhael https://www.linkedin.com/in/joseph-mikhael-8432188/ is Professor at the Translational Genomics Research Institute and Chief Medical Officer of the International Myeloma Foundation. With extensive expertise in plasma cell disorders, his work focuses on advancing clinical research, patient education, and addressing disparities in multiple myeloma care. What you will learn: (00:00) Highlight (00:38) Introduction (12:38) Quadruplet therapy today (21:39) Car-T outcomes (24:42) Bispecifics in treatment (33:38) Bone health support (34:38) Early intervention debate (38:50) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/oncologyinsights Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/